FDA Chronic Fatigue Guidance Takes Flexible Stand On Patient-Reported Outcomes
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trial efficacy endpoints for investigational CFS/ME drugs should include patient-reported symptoms, but FDA is open to the use of instruments evaluated in other populations for this purpose, agency says in a new draft guidance.
You may also be interested in...
“Patient Voice” Report Puts Chronic Fatigue Symptoms, Treatments In Benefit/Risk Framework
FDA report on CFS/myalgic encephalomyelitis is first of its kind from the patient-focused drug development initiative under PDUFA V. Incorporating comments from hundreds of patients and caregivers into a structured framework shows how the input may support a benefit/risk assessment for new products.
Hemispherx Vows To Fight FDA’s Second Rejection Of Ampligen
In a “complete response” letter, FDA requested at least one new clinical trial, along with nonclinical studies and numerous data analyses, before approval of the chronic fatigue syndrome drug. Hemispherx continues to assert the existing data support approval and plans an appeal to FDA’s Office of New Drugs.
Chronic Fatigue Syndrome Drug Development Efforts Get A Boost From FDA
Agency is undertaking a series of activities with patients, advocacy groups and other stakeholders aimed at spurring development of new treatments. Hemispherx is hoping its investigational drug Ampligen, currently under FDA review, will become an early beneficiary of new statutory provisions on expedited approval.